Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;10(9):842-856.
doi: 10.1016/j.trecan.2024.06.007. Epub 2024 Jul 16.

Transcriptomic subtyping of gastrointestinal malignancies

Affiliations
Free article
Review

Transcriptomic subtyping of gastrointestinal malignancies

Tim R de Back et al. Trends Cancer. 2024 Sep.
Free article

Abstract

Gastrointestinal (GI) cancers are highly heterogeneous at multiple levels. Tumor heterogeneity can be captured by molecular profiling, such as genetic, epigenetic, proteomic, and transcriptomic classification. Transcriptomic subtyping has the advantage of combining genetic and epigenetic information, cancer cell-intrinsic properties, and the tumor microenvironment (TME). Unsupervised transcriptomic subtyping systems of different GI malignancies have gained interest because they reveal shared biological features across cancers and bear prognostic and predictive value. Importantly, transcriptomic subtypes accurately reflect complex phenotypic states varying not only per tumor region, but also throughout disease progression, with consequences for clinical management. Here, we discuss methodologies of transcriptomic subtyping, proposed taxonomies for GI malignancies, and the challenges posed to clinical implementation, highlighting opportunities for future transcriptomic profiling efforts to optimize clinical impact.

Keywords: colorectal cancer; gastric cancer; gastrointestinal malignancies; pancreatic ductal adenocarcinoma; personalized medicine; transcriptomic subtyping.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests L.V. received consultancy fees from Bayer, MSD, Genentech, Servier, Roche, Novartis, and Pierre Fabre, but these had no relation to the content of this publication. L.V. is an employee of Genentech. The other authors declare no competing interests.

References

Publication types

MeSH terms

Substances

LinkOut - more resources